Prospective study of Ombitasvir/Paritaprevir/Ritonavir for HCV genotype 1 intected Japanese patients including patients with chronic kidney disease

Prospective study of Ombitasvir/Paritaprevir/Ritonavir for HCV genotype 1 intected Japanese patients including patients with chronic kidney disease - IFN free OPR study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000020626

Enrollment

200

Registered

2016-01-19

Start date

2016-01-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HCV genotype 1 infected chronic liver disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: HCV genotype 1 infected patients with chronic liver disease Patients satisfied the public indication for Ombitasvir/Paritaprevir/Ritonavir

Exclusion criteria

Exclusion criteria: Pregnant woman Decompensated cirrhosis hepatocellular carcinoma Doctors judge as inappropriate

Design outcomes

Primary

Measure	Time frame
Sustained viral response (SVR) 12	—

Countries

Japan

Contacts

Public ContactAkihiro Tamori

Osaka City University Graduated School of edicine Department of Hepatology

atamori@med.osaka-cu.ac.jp06-6645-3811

Outcome results